Full-Time

Senior Director of Enterprise Security Architecture

Posted on 8/21/2026

Deadline 9/18/26
Cencora

Cencora

10,001+ employees

Global pharmaceutical distribution and services provider

Compensation Overview

$141.6k - $283.3k/yr

+ Geographic salary variation

Delaware, USA + 4 more

More locations: Texas, USA | Philadelphia, PA, USA | Arizona, USA | New Jersey, USA

Remote

Bachelor's, Master's

Category
Engineering Management (1)
Required Skills
ERP
Risk Management

Get referred to Cencora

See people who can refer or advise you

Requirements
  • A bachelor's degree in computer science, software engineering, systems engineering, information technology, cybersecurity, or a related field, or equivalent experience is required.
  • A master's degree in Business Administration, Computer Science, Information Technology, or another related discipline, or equivalent related experience, is required.
  • At least 12 years of directly related or relevant experience, including at least 8 years in a managerial capacity, preferably in information security, is required.
  • Preferred certifications include Certified Cloud Security Professional, Certified Information Systems Security Professional, Sherwood Applied Business Security Architecture, Open Group Architecture Framework, Certified in Risk and Information Systems Control, Certification in Information Security Strategy Management, Microsoft Certified: Cybersecurity Architect Expert, Information Technology Infrastructure Library, Offensive Security Certified Professional, and Project Management Professional.
  • Required technical skills include IT risk management, IT controls, cyber attack mitigation, enterprise IT management, cloud security, network security, identity and access management, application security, service level maintenance, information security strategy continuity, threat modelling, and information security strategy standards including SOX, ISO 27001/27002, COBIT, ITIL, NIST, and PCI.
  • Knowledge of Microsoft Office Suite, security tools such as CSPM, CWPP, CDR, CNAPP, SIEM, EDR, email security gateways, SOAR, firewalls, antivirus, VPN, IDS/IPS, and proxies; security testing tools; threat intelligence tools; and vulnerability testing tools is required.
  • Behavioral capabilities include coaching and mentoring, creativity and innovation, decision making, leadership, people management, planning, and risk-taking.
Responsibilities
  • Define and maintain the enterprise security architecture vision and multi-year roadmap.
  • Align security architecture with corporate strategy, digital transformation, and technology modernization initiatives.
  • Establish target-state architectures incorporating Zero Trust principles in collaboration with Information Security and Technology leaders.
  • Translate risk appetite into enforceable architectural guardrails.
  • Develop and maintain standardized reference architectures for cloud and hybrid infrastructure, identity and access management, data protection and privacy, network segmentation, application security, AI/GenAI security, and OT/IoT.
  • Ensure security-by-design integration into the software development lifecycle and platform engineering models.
  • Govern architecture artifacts across global business units.
  • Chair or co-chair the Security Architecture Review Board.
  • Define security architecture review processes and risk exception workflows.
  • Establish measurable design assurance criteria.
  • Partner with Enterprise Architecture for integrated technology governance.
  • Translate regulatory and risk requirements into technical control standards.
  • Ensure compliance with global regulatory regimes such as HIPAA, GDPR, SOX, and FDA/GxP where applicable.
  • Maintain or enforce the enterprise security standards library mapped to NIST, ISO, SOC 2, PCI, HIPAA, and GDPR.
  • Enable reusable security requirement models for programs and projects.
  • Drive automation of control validation and policy-as-code enforcement.
  • Support regulatory readiness across global jurisdictions.
  • Ensure architecture supports data residency and sovereignty obligations.
  • Collaborate with Legal, Privacy, and Compliance on emerging regulatory impacts.
  • Provide defensible architecture documentation for audit and regulatory review.
  • Lead security architecture assessments for acquisitions.
  • Define integration and divestiture security blueprints.
  • Support large-scale ERP, digital, AI, and cloud transformation programs.
  • Establish rapid risk assessment models for new technologies.
  • Establish KPIs, OKRs, and performance dashboards.
  • Track control design effectiveness and systemic risk reduction.
  • Integrate architecture insights with cyber analytics programs.
  • Report enterprise architecture risk posture to executive leadership.
  • Lead the global team of security domain architects.
  • Define the operating model across centralized and federated teams.
  • Establish architecture career paths and technical competency frameworks.
  • Manage enterprise financial management and planning.
Desired Qualifications
  • Preferred certifications include Certified Cloud Security Professional, Certified Information Systems Security Professional, Sherwood Applied Business Security Architecture, Open Group Architecture Framework, Certified in Risk and Information Systems Control, Certification in Information Security Strategy Management, Microsoft Certified: Cybersecurity Architect Expert, Information Technology Infrastructure Library, Offensive Security Certified Professional, and Project Management Professional.

Cencora provides global pharmaceutical distribution and a range of services, including specialty pharmacy, consulting, supply-chain management, patient support programs, and data analytics for healthcare providers, manufacturers, and veterinary practices. It works by combining physical drug distribution with value-added services such as inventory management, regulatory compliance guidance, patient support, and data-driven insights to optimize supply chains and outcomes. The company differentiates itself with an integrated, end-to-end offering that spans distribution, clinical services, analytics, and advisory support to help clients run more efficient operations and lower costs. Its goal is to improve healthcare outcomes by delivering comprehensive pharmaceutical solutions that enable better care and lower overall expenses.

Company Size

10,001+

Company Stage

IPO

Headquarters

Pennsylvania

Founded

1907

Get referred to Cencora

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 5, 2026: Cencora raised fiscal 2026 EPS guidance to $17.75-$17.95.
  • July 31, 2026: Cencora expanded its revolver to $7 billion, extending maturity to 2031.
  • Cencora completed $1 billion in share repurchases during Q3, reducing diluted shares to 194 million.

What critics are saying

  • Baltimore dropped its opioid case after Maryland's April 2026 ruling vacated Cencora's $152 million verdict.
  • Cencora directors still face a $111.3 million opioid settlement, confirming persistent litigation over legacy conduct.
  • A California labor class action and heavy debt coverage pressure threaten margins before fiscal 2027.

What makes Cencora unique

  • Cencora's specialty platform, including OneOncology and RCA MSOs, drives outsized growth on August 5, 2026.
  • Nucleus inventory tools embed Cencora inside specialty physician practices' workflows across 20+ sites.
  • Global distribution plus World Courier and European 3PL give Cencora reach beyond U.S. drug flow.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Parental Leave

Adoption Assistance

Infertility Coverage

Family Planning Benefits

Behavioral Health Solutions

Professional Development Budget

Training Programs

Company News

Yahoo Finance
Aug 14th, 2026
Cencora beats Q2 profit estimates as specialty pharma platform drives growth

Cencora reported second-quarter revenue of $84.75 billion, slightly above analyst estimates of $84.43 billion, representing 5.1% year-on-year growth. Adjusted earnings per share came in at $4.48, beating consensus estimates of $4.35 by 3%. Management attributed the performance to strength in specialty pharmaceuticals, particularly through Management Services Organisations like OneOncology and RCA. CEO Robert Mauch highlighted the company's positioning in specialty care, stating, "Our specialty platform supports growth across the healthcare ecosystem." The company raised its full-year adjusted EPS guidance to $17.85 at the midpoint. Operating margin held steady at 1.3%, matching the same quarter last year. During the earnings call, analysts questioned management about biosimilar opportunities, specialty logistics competition, and potential policy risks from proposed ASP rule changes.

Yahoo Finance
Aug 12th, 2026
Cencora raises FY2026 guidance after Q3 EPS jumps 12%, buys back $1B in shares

Cencora reported strong third-quarter results for fiscal year 2026, driven by execution across its business units and investments in its specialty positioning. The pharmaceutical distributor achieved double-digit adjusted operating income growth and 12% earnings per share growth in the quarter. The company conducted $1 billion in opportunistic share repurchases during the period. Based on its performance and confidence in continued execution, Cencora raised its fiscal 2026 EPS guidance. President and CEO Robert Mauch credited the results to the company's team members and their commitment to providing solutions for customers. He highlighted the strength of Cencora's portfolio and its pharmaceutical-centric strategy as the company approaches the end of its fiscal year. The earnings call was held on 5 August 2026, with senior leadership including Mauch and CFO Eva Boratto participating.

MarketScreener
Aug 5th, 2026
Cencora boosts credit facility to $7B, extends maturity to 2031

Cencora and its subsidiary Innomar Strategies have amended their credit agreement, increasing their multi-currency revolving credit facility from $5.5 billion to $7.0 billion. The facility's maturity date has been extended to July 2031. Interest rates on borrowings range from 69.5 to 110 basis points over various term rates, depending on Cencora's public debt ratings. The agreement includes covenants such as a maximum financial leverage ratio. Separately, on 31 July 2026, Cencora amended its receivables securitisation facility, reducing it from $1.5 billion to $1.0 billion whilst increasing the accordion feature from $500 million to $1.0 billion. This gives the company the option to expand commitments by up to $1.0 billion, subject to bank approval.

Yahoo Finance
Aug 1st, 2026
Cencora Q3 earnings preview: analysts expect $4.37 EPS on $84.89B revenue

Wall Street analysts expect Cencora to report quarterly earnings of $4.37 per share, marking a 9.3% year-over-year increase. Revenues are projected to reach $84.89 billion, up 5.2% from the same quarter last year. Over the past 30 days, the consensus earnings per share estimate has been revised upward by 1.3%. Analysts forecast revenue from Total US Healthcare Solutions at $75 billion, representing 2.9% year-over-year growth. International Healthcare Solutions revenue is expected to remain flat at $7.79 billion. Operating income projections show US Healthcare Solutions at $940.87 million and International Healthcare Solutions at $158.45 million. Cencora shares have risen 5.3% over the past month and hold a Zacks Rank of 2, indicating expected outperformance versus the broader market.

Yahoo Finance
Jul 13th, 2026
CVS Health leads Q1 health insurance earnings as Cencora misses revenue estimates by 3.9%

CVS Health led health insurance providers in Q1, with revenues of $100.4 billion, up 6.2% year on year and beating analyst expectations by 6.3%. The company exceeded full-year EPS guidance estimates. The 12 health insurance provider stocks tracked reported strong Q1 results overall. Revenues beat consensus estimates by 1.4%, whilst next quarter's guidance was in line. Share prices rose 37.4% on average following the earnings announcements. Cencora performed weakest amongst peers, reporting revenues of $78.36 billion, up 3.8% year on year. This fell short of analyst expectations by 3.9%. The stock has remained flat since reporting and currently trades at $303.53. The industry faces tailwinds from an ageing population and improved data analytics, but regulatory scrutiny on pricing and medical cost inflation may impact margins.